Nouscom is a Basel-based clinical-stage biotech developing next-generation neoantigen-targeted cancer immunotherapies, spanning early-stage cancer interception through late-stage metastatic disease, on a proprietary viral-vector platform. Its lead asset NOUS-209 is an off-the-shelf immunotherapy in advanced clinical development for cancer interception in Lynch syndrome carriers and for treating MSI metastatic colorectal cancer, and holds FDA Fast Track designation for the Lynch syndrome indication; the clinical portfolio also includes NOUS-PEV, a personalized neoantigen vaccine with published Phase 1b data. Founded in 2015, the company is backed by an international life-science investor syndicate and is advancing NOUS-209 into a global registration-enabling trial.
1
Round
1
Industry
5
Tags
Oct 19, 2026
Latest raise
Funding activity · 1 round
Oct 19, 2026
EUR 120M
Series C+
Led by M Ventures
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
